Reference intervals: A novel approach to detect drug abuse in a pain patient population

Journal of Opioid Management

Volumn 6, Issue 5, 2010, Pages 341-350

  Pesce, Amadeo ^a   West, Cameron ^a   West, Robert ^a   Crews, Bridgit ^a   Mikel, Charles ^a   Almazan, Perla ^a   Latyshev, Sergey ^a   Rosenthal, Murray ^a   Horn, Paul ^b,c  

^a Millennium Research Institute   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Drug abuse; Drug testing; Morphine; Pain patients; Reference interval; Upper limits of excretion

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; 7 AMINOCLONAZEPAM; ALPHA HYDROXYALPRAZOLAM; AMPHETAMINE; BUPRENORPHINE; CARISOPRODOL; COCAINE DERIVATIVE; CODEINE; DEXTROPROPOXYPHENE; DRUG METABOLITE; FENTANYL; HYDROCODONE; HYDROMORPHONE; LORAZEPAM; MEPROBAMATE; METHADONE; METHAMPHETAMINE; MORPHINE; MORPHINE 6 ACETATE; NORBUPRENORPHINE; NORDAZEPAM; NORPROPOXYPHENE; OPIATE; OXAZEPAM; OXYCODONE; OXYMORPHONE; PHENCYCLIDINE; TEMAZEPAM; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; NARCOTIC ANALGESIC AGENT;

ARTICLE; CHRONIC PAIN; COHORT ANALYSIS; DRUG ABUSE; DRUG EXCRETION; DRUG METABOLISM; HUMAN; MAJOR CLINICAL STUDY; MASS SPECTROMETRY; MATHEMATICAL MODEL; OPIATE ADDICTION; PAIN; REFERENCE VALUE; URINALYSIS; URINARY EXCRETION; METHODOLOGY; SUBSTANCE ABUSE; THEORETICAL MODEL; URINE;

ANALGESICS, OPIOID; HUMANS; MODELS, THEORETICAL; PAIN; SUBSTANCE ABUSE DETECTION;

EID: 78349291623     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2010.0031     Document Type: Article

References (20)

1. Kuehn BM: Efforts aim to curb opioid deaths, injuries. JAMA. 2009; 301(12): 1213-1215.
2. Manchikanti L, Damron KS, McManus C, et al.: Patterns of illicit drug use and opioid abuse in patients with chronic pain at initial evaluation: A prospective observational study. Pain Physician. 2004; 7: 431-437.
3. Manchikanti L, Cash KA, Damron KS, et al.: Controlled substance abuse and illicit drug use in chronic pain patients: An evaluation of multiple variables. Pain Physician. 2006; 9: 215-226.
4. Reisfield GM, Wilson GR: Are some physicians unwitting enablers of prescription opioid abuse? J Opioid Manag. 2009; 5(2): 71-73.
5. Sloan PA: Opioid risk management: Understanding FDA mandated risk evaluation and mitigation strategies (REMS). J Opioid Manag. 2009; 5(3): 131-133.
6. Smith HS, Kirsh KL, Passik SD: Chronic opioid therapy issues associated with opioid abuse potential. J Opioid Manag. 2009; 5(5): 287-300.
7. Trescot AM, Helm S, Hansen H, et al.: Opioids in the management of chronic non-cancer pain: An update of American Society of Interventional Pain Physicians' (ASIPP) Guidelines. Pain Physician. 2008; 11: S5-S62.
8. Chou R, Fanciullo G, Fine P, et al.: Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain. 2009; 10(2): 113-130.
9. Manchikanti L, Atluri S, Trescot AM, et al.: Monitoring opioid adherence in chronic pain patients: Tools, techniques, and utility. Pain Physician. 2008; 11(2 Suppl): S155-S180.
10. Manchikanti L, Manchukonda R, Pampati, et al.: Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids? Pain Physician. 2006; 9: 123-129.
11. Cone EJ, Caplan YH, Black DL, et al.: Urine drug testing of chronic pain patients: Licit and illicit drug patterns. J Anal Toxicol. 2008; 32: 530-543.
12. Baselt RC: Disposition of Toxic Drugs and Chemicals in Man. 7th ed. Foster City, CA: Biomedical Publications, 2004.
13. White RM: And Black ML Pain Management Testing Reference. 1st ed. Washington, DC: AACC Press, 2007: 285.
14. Horn P: Reference intervals and clinical decision limits. In Kaplan L, Pesce A (eds.): Clinical Chemistry: Theory, Analysis, Correlation. 5th Ed. St. Louis: Mosby/Elsevier, 2010: 439-455.
15. Horn PA, Pesce AJ: Reference Intervals: A User's Guide. Washington, DC: AACC Press, 2005.
16. Horowitz GL, Altaie S, Boyd JC, et al.: Defining, Establishing, and Verifying Rerference Intervals in the Clinical Laboratory; Approved Guideline. 3rd Ed. CLSI Document: C-28-A3. Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
17. Mohsin S, Yang Y, Zumwalt M: Quantitative analysis of opiates in urine using RRHT LC/MS/MS. Agilent Application. Santa Clara, CA: Agilent Technologies, Inc.
18. Target compound identification and quantitation procedure. Agilent Technologies, Inc [MSD ChemStation Data Analysis]. Accessed March 20, 2002.
19. Crews B, Mikel C, Latyshev S, et al.: 6-Acetylmorphine detected in the absence of morphine in pain management patients. Ther Drug Monit. 2009; 31: 749-752.
20. Mikel C, Almazan P, West R, et al.: LC-MS/MS extends the range of drug analysis in pain patients. Ther Drug Monit. 2009; 31(6): 746-748.